Articles: PDF OnlyAge, Severity, and Pharmacotherapy in Autism/Pervasive Developmental DisordersToichi, Motomi MD, PhD; Findling, Robert L. MD Author Information CME article by Motomi Toichi, MD, PhD, Director of Mental Health, Associate Professor, Health and Medical Services Center, Shiga University, Shiga, Japan; and Robert L. Findling, MD, Director, Division of Child and Adolescent Psychiatry, Associate Professor of Psychiatry, Case Western Reserve University/University Hospitals of Cleveland Dr. Toichi has disclosed that he has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. Dr. Findling has disclosed that his research is supported in part by, he is a consultant to, and/or is on the speakers' bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, and Solvay. The use of haloperidol, fluphenazine, risperidone, olanzapine, quetiapine, clozapine, clomipramine, fluvoxamine, fluoxetine, sertraline, paroxetine, methylphenidate, naltrexone, clonidine, and propranolol has not been approved by the U.S. Food and Drug Administration for the treatment of autism. International Drug Therapy Newsletter: November 2002 - Volume 37 - Issue 11 - p 81-87 Buy Abstract Learning Objectives: After reading this article, the practitioner should be able to: Describe problematic behaviors associated with autism, and their changes with age and comorbid cognitive impairment. Discuss the risks and benefits of the major pharmacotherapy options in autism and pervasive developmental disorders. Cite patient factors that affect responsivity to treatment. © 2002 Lippincott Williams & Wilkins, Inc.